Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

1.

Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.

Waters DD, Ho JE, Boekholdt SM, DeMicco DA, Kastelein JJ, Messig M, Breazna A, Pedersen TR.

J Am Coll Cardiol. 2013 Jan 15;61(2):148-52. doi: 10.1016/j.jacc.2012.09.042. Epub 2012 Dec 5.

PMID:
23219296
[PubMed - indexed for MEDLINE]
Free Article
2.

Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model.

Shinozaki T, Matsuyama Y, Iimuro S, Umegaki H, Sakurai T, Araki A, Ohashi Y, Ito H; Japanese Elderly Diabetes Intervention Trial Research Group.

Geriatr Gerontol Int. 2012 Apr;12 Suppl 1:88-102. doi: 10.1111/j.1447-0594.2011.00816.x.

PMID:
22435944
[PubMed - indexed for MEDLINE]
3.

Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.

Callahan A, Amarenco P, Goldstein LB, Sillesen H, Messig M, Samsa GP, Altafullah I, Ledbetter LY, MacLeod MJ, Scott R, Hennerici M, Zivin JA, Welch KM; SPARCL Investigators.

Arch Neurol. 2011 Oct;68(10):1245-51. doi: 10.1001/archneurol.2011.146. Epub 2011 Jun 13.

PMID:
21670382
[PubMed - indexed for MEDLINE]
4.

Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial).

LaRosa JC, Deedwania PC, Shepherd J, Wenger NK, Greten H, DeMicco DA, Breazna A; TNT Investigators.

Am J Cardiol. 2010 Feb 1;105(3):283-7. doi: 10.1016/j.amjcard.2009.09.025. Epub 2009 Dec 22.

PMID:
20102935
[PubMed - indexed for MEDLINE]
5.

Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease.

Shepherd J, Kastelein JP, Bittner VA, Carmena R, Deedwania PC, Breazna A, Dobson S, Wilson DJ, Zuckerman AL, Wenger NK; Treating to New Targets Steering Committee and Investigators.

Mayo Clin Proc. 2008 Aug;83(8):870-9.

PMID:
18674471
[PubMed - indexed for MEDLINE]
6.
7.

Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.

Plosker GL, Lyseng-Williamson KA.

Pharmacoeconomics. 2007;25(12):1031-53. Review.

PMID:
18047388
[PubMed - indexed for MEDLINE]
8.

Role of statins for the primary prevention of cardiovascular disease in patients with type 2 diabetes mellitus.

Riche DM, McClendon KS.

Am J Health Syst Pharm. 2007 Aug 1;64(15):1603-10. Review.

PMID:
17646562
[PubMed - indexed for MEDLINE]
9.

Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).

Neil HA, DeMicco DA, Luo D, Betteridge DJ, Colhoun HM, Durrington PN, Livingstone SJ, Fuller JH, Hitman GA; CARDS Study Investigators.

Diabetes Care. 2006 Nov;29(11):2378-84.

PMID:
17065671
[PubMed - indexed for MEDLINE]
10.

Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.

Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D.

Diabetes Care. 2006 Jun;29(6):1220-6.

PMID:
16731999
[PubMed - indexed for MEDLINE]
11.

Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.

Nesto RW.

Am J Cardiovasc Drugs. 2005;5(6):379-87. Review.

PMID:
16259526
[PubMed - indexed for MEDLINE]
12.
13.

Lipid management with statins in type 2 diabetes mellitus.

Irons BK, Kroon LA.

Ann Pharmacother. 2005 Oct;39(10):1714-9. Epub 2005 Aug 23. Review.

PMID:
16118264
[PubMed - indexed for MEDLINE]
14.
15.

Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

Sever PS, Poulter NR, Dahlöf B, Wedel H, Collins R, Beevers G, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J.

Diabetes Care. 2005 May;28(5):1151-7.

PMID:
15855581
[PubMed - indexed for MEDLINE]
16.

CARDS on the table: should everybody with type 2 diabetes take a statin?

Lee JD, Morrissey JR, Mikhailidis DP, Patel V.

Curr Med Res Opin. 2005 Mar;21(3):357-62.

PMID:
15811203
[PubMed - indexed for MEDLINE]
17.

Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus.

Croom KF, Plosker GL.

Drugs. 2005;65(1):137-52. Review.

PMID:
15610062
[PubMed - indexed for MEDLINE]
18.

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH; CARDS investigators.

Lancet. 2004 Aug 21-27;364(9435):685-96.

PMID:
15325833
[PubMed - indexed for MEDLINE]
19.

Clinical trials and lipid guidelines for type II diabetes.

Prisant LM.

J Clin Pharmacol. 2004 Apr;44(4):423-30. Review.

PMID:
15051751
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk